The Democratic Republic of the Congo’s ongoing Bundibugyo Ebola outbreak, now exceeding 7,000 cases and 3,400 deaths across seven provinces since its mid-May confirmation, dominates trader attention for 2026 markets. Recent spread to the remote northwestern South-Ubangi province via an infected traveler who crossed multiple borders has heightened concerns about export to neighboring Central African Republic and Republic of the Congo. Government data show declining incidence in the Ituri epicenter, yet weak surveillance, conflict-driven displacement, and school reopenings continue to fuel new transmission chains. Uganda’s smaller concurrent cluster ended in June with no further reports. Vaccination campaigns targeting frontline workers and expanded contact tracing represent key near-term catalysts, though the absence of a licensed Bundibugyo-specific vaccine limits containment speed. Traders monitor border movements and WHO assessments for signals of wider regional risk.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourWhich countries will have an Ebola case in 2026?
$38,659 Vol.
South Sudan
68%
Rwanda
20%
Burundi
48%
United States
19%
Canada
23%
Kenya
23%
India
46%
Republic of the Congo
26%
Nigeria
50%
Ethiopia
52%
Somalia
36%
China
14%
$38,659 Vol.
South Sudan
68%
Rwanda
20%
Burundi
48%
United States
19%
Canada
23%
Kenya
23%
India
46%
Republic of the Congo
26%
Nigeria
50%
Ethiopia
52%
Somalia
36%
China
14%
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Marché ouvert : May 22, 2026, 12:35 PM ET
Résolveur
0x65070BE91...Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Résolveur
0x65070BE91...The Democratic Republic of the Congo’s ongoing Bundibugyo Ebola outbreak, now exceeding 7,000 cases and 3,400 deaths across seven provinces since its mid-May confirmation, dominates trader attention for 2026 markets. Recent spread to the remote northwestern South-Ubangi province via an infected traveler who crossed multiple borders has heightened concerns about export to neighboring Central African Republic and Republic of the Congo. Government data show declining incidence in the Ituri epicenter, yet weak surveillance, conflict-driven displacement, and school reopenings continue to fuel new transmission chains. Uganda’s smaller concurrent cluster ended in June with no further reports. Vaccination campaigns targeting frontline workers and expanded contact tracing represent key near-term catalysts, though the absence of a licensed Bundibugyo-specific vaccine limits containment speed. Traders monitor border movements and WHO assessments for signals of wider regional risk.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour


Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes